[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bariatric-surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bariatric-surgery":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,83,0,25,[9,48,73,104,139,166,199,228,258,289,311,334,357,389,421,449,477,506,539,566,585,609,633,660,684],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100593837","transition-to-ambulatory-bariatric-surgery-tabs-trial-100593837",false,"NCT07011628","Transition to Ambulatory Bariatric Surgery (TABS) Trial","TABS","Inclusion Criteria:\n\n* BMI ≤ 60 kg\u002Fm2\n* Primary Sleeve gastrectomy or Gastric Bypass,\n* Undergoing bariatric surgery at sponsor site\n\nExclusion Criteria:\n\n* Type 1 Diabetes\n* Myocardial Infarction\n* Unstable Angina or Heart Failure\n* Prior Stroke\n* Solid organ transplantation\n* Systemic glucocorticoid prior 28 days\n* Severe Obstructive Sleep Apnea\n* Uncontrolled Hypertension (Systolic \\> 150, Diastolic \\> 90)\n* Untreated Hyperthyroidism\n* Chronic Kidney Disease (EGFR \\\u003C 60)\n* Current anticoagulant use,\n* Poorly controlled Type 2 diabetes (Hemoglobin A1c in last 3 months \\> 8.5%)\n* Chronic opioid use\n* Insulin dependence.\n* Need for extended venous thromboembolic event prophylaxis,\n* \\> 1 lifetime bariatric surgery (revisional or conversion bariatric surgery)\n* Patient lives \\> 130 miles from the hospital.\n* Tobacco use in last 12 months\n* Desire to become pregnant or active pregnancy\n* Prisoners\n* Unable or unwilling to follow-up\n* Unable to understand or provide consent","ALL","25 Years","55 Years",{"count":21,"type":22},200,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study will compare same day discharge and at least one night stay in the hospital after bariatric surgery. Patients undergoing bariatric surgery will be randomized (i.e. have an equal chance of either plan) to either group. The study's primary outcome is the frequency patients in the study require a visit to the emergency room within 7 days of their surgery.",[28,29],"Obesity and Obesity-related Medical Conditions","Bariatric Surgery",[31,32,33,34],"ambulatory surgery","same day discharge","gastric bypass","sleeve gastrectomy","NOT_YET_RECRUITING","2026-08-17",{"date":38,"type":39},"2026-08-18","ACTUAL",{"date":41,"type":22},"2026-10-01",{"date":43,"type":22},"2028-05-01",{"name":45,"class":46},"Vanderbilt University Medical Center","OTHER",1,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":55,"minAge":4,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":4},"100651339","early-phase-1-opportunistic-salpingectomy-during-bariatric-surgery-for-ovarian-cancer-prevention-100651339","NCT07761416","Opportunistic Salpingectomy During Bariatric Surgery for Ovarian Cancer Prevention","Opportunistic Salpingectomy at Time of Bariatric Surgery for Ovarian Cancer Prevention: a Feasibility Study","Inclusion Criteria:\n\n* Individuals with fallopian tubes (no prior salpingectomy\u002Fsalpingo-oophorectomy) who are undergoing an elective MBS and have completed child-bearing\n\nExclusion Criteria:\n\n* unable to provide informed consent","FEMALE",{"count":57,"type":22},66,[59],"EARLY_PHASE1","Ovarian cancer is a deadly disease that is hard to detect early and difficult to treat. Research shows that most ovarian cancers actually start in the fallopian tubes, not the ovaries. Removing the fallopian tubes (a procedure called salpingectomy) can lower the risk of ovarian cancer by about 80%. This procedure has no added risk to the patient, but does lead to sterilization and thus it is only offered to individuals who have completed child-bearing. Adding salpingectomy to another surgery that a patient is undergoing is called opportunistic salpingectomy and is already standard of practice in many gynecologic surgeries, such as hysterectomy. However, it is not yet commonly offered during weight-loss (bariatric) surgery, even though many patients having this surgery could benefit. This study will test whether it is practical and safe to offer fallopian tube removal during bariatric surgery at three hospitals in Canada. Patients who are eligible and interested will be invited to have their fallopian tubes removed at the same time as their planned weight-loss surgery. The research team will track whether the procedure can be completed successfully, whether there are any added complications, and how much extra time or resources are needed. The goal is to help make this cancer-prevention option available to more people.",[62,29,63],"Ovarian Cancer","Opportunistic Salpingectomy","2026-08-10",{"date":66,"type":39},"2026-08-12",{"date":68,"type":22},"2026-08-01",{"date":70,"type":22},"2027-03-30",{"name":72,"class":46},"St. Joseph's Healthcare Hamilton",{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100604979","protein-supplementation-and-resistance-training-to-prevent-fat-free-mass-loss-following-metabolic-bariatric-surgery-100604979","NCT07156552","Protein Supplementation and Resistance Training to Prevent Fat-Free Mass Loss Following Metabolic-Bariatric Surgery","Effectiveness of Protein SupplementatIon Combined With Resistance Exercise Training to Counteract Disproportional Fat-Free Mass Loss Following Metabolic-Bariatric Surgery: The ENRICHED Study","ENRICHED","Inclusion Criteria:\n\n* A scheduled metabolic-bariatric surgery (i.e. RYGB or Sleeve Gastrectomy)\n* Participation in the NOK care program\n* Able to understand and perform the study procedures\n\nExclusion Criteria:\n\n* Allergic or sensitive for milk proteins, or lactose intolerant\n* Diagnosed renal insufficiency\n* Diagnosed intestinal diseases influencing the uptake of protein (i.e. active inflammatory bowel disease","18 Years",{"count":83,"type":22},400,[25],"The goal of this clinical trial is to investigate the effects of daily protein supplementation and participation in a weekly supervised resistance training program on the prevention of excessive muscle mass loss following bariatric surgery. Patients treated at one of the participating centers will be invited to participate and will be randomly assigned to one of two groups.\n\nParticipants in group 1 will receive standard postoperative care as currently provided. Participants in group 2 will also receive standard care, but in addition, they will be asked to consume extra protein daily and take part in a supervised resistance training session once a week.\n\nPrevious research has shown that approximately one in five patients undergoing bariatric surgery experiences excessive muscle loss after the surgery. It is known that resistance training and protein intake can help maintain and even improve muscle mass. However, limited research has been conducted on the combined effects of protein supplementation and resistance training in patients after bariatric surgery. Therefore, the aim of this trial is to determine whether participants receiving the additional intervention experience less muscle mass loss compared to those receiving standard care alone.",[29,87],"Fat Free Mass",[89,29,90,91,92,93],"Metabolic-Bariatric Surgery","Sleeve Gastrectomy","Roux-en Y Gastric Bypass","Protein Supplementation","Resistance Training","RECRUITING",{"date":96,"type":39},"2026-08-11",{"date":98,"type":39},"2025-06-20",{"date":100,"type":22},"2027-12-31",{"name":102,"class":46},"Radboud University Medical Center",2,{"id":105,"slug":106,"hasResults":12,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":12,"sex":17,"minAge":112,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":23,"phases":116,"briefSummary":117,"conditions":118,"keywords":122,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":135,"completionDateStruct":136,"leadSponsor":138,"locationsCount":4},"100651335","metabolic-flux-analysis-in-metabolic-dysfunction-associated-steatotic-liver-disease-100651335","NCT07760909","Metabolic Flux Analysis in Metabolic Dysfunction-Associated Steatotic Liver Disease","Metabolic Flux Analysis in MASLD","MASLD","Inclusion Criteria:\n\n* Scheduled and clinically cleared for protocol-eligible bariatric surgery at Vanderbilt University Medical Center.\n* BMI ≥40 kg\u002Fm², or BMI \\>35 kg\u002Fm² with at least one obesity-associated comorbidity, such as type 2 diabetes, cardiovascular disease, hypertension, hyperlipidemia, obstructive sleep apnea, MASLD, osteoarthritis, or polycystic ovarian syndrome.\n* Able and willing to complete study procedures, including informed consent, questionnaires, blood draws, MRI\u002FMRE imaging, stable isotope tracer infusion, and research tissue collection during planned bariatric surgery.\n* Able to provide informed consent in English.\n\nExclusion Criteria:\n\n* Contraindication to MRI\u002FMRE, including implanted cardiac defibrillator, pacemaker, or other MRI-incompatible implanted device.\n* Prior gastric or intestinal surgery, pancreatic surgery, or other prior surgery that, in the judgment of the study team or bariatric surgeon, would interfere with study procedures or outcome interpretation.\n* Active cancer or ongoing cancer treatment.\n* Presence or history of HIV infection.\n* Alcohol use above study-defined limits: more than 14 alcoholic drinks per week for men or more than 7 alcoholic drinks per week for women, or illicit drug use that would interfere with safe participation or interpretation of study results.\n* Anemia or other hematologic condition that would increase risk from study blood collection.\n* Abnormal ECG or clinically significant cardiovascular finding that would increase risk from study procedures.\n* Impaired renal function or other clinically significant condition that would increase risk from study participation.\n* Known Wilson's disease, alpha-1 antitrypsin deficiency, hemochromatosis, or other non-MASLD chronic liver disease that would confound interpretation of study outcomes.\n* Any medical, surgical, or safety condition that, in the judgment of the PI, clinical co-investigator, CRC staff, anesthesia team, or bariatric surgeon, would make participation unsafe or interfere with completion of study procedures.","21 Years","70 Years",{"count":115,"type":22},20,[25],"This prospective, single-center pilot study will evaluate metabolic flux dysregulation in adults with obesity and suspected or confirmed metabolic dysfunction-associated steatotic liver disease (MASLD) who are scheduled for protocol-eligible bariatric surgery at Vanderbilt University Medical Center. Participants will undergo research assessments before surgery, during the planned bariatric surgery encounter, and approximately 6 months after surgery. The study uses non-radioactive stable isotope tracer infusions, serial blood sampling, abdominal MRI\u002FMRE, and research tissue specimens collected only during clinically planned bariatric surgery to quantify hepatic and extrahepatic metabolic fluxes. The primary objective is to determine how hepatic citric acid cycle flux and related metabolic pathways change after bariatric surgery and how these metabolic measures relate to liver fat, liver stiffness, and biopsy-graded MASLD\u002FMASH severity.",[119,120,121,29],"Metabolic Dysfunction-Associated Steatotic Liver Disease","Metabolic Dysfunction-Associated Steatohepatitis","Obesity",[110,123,124,125,126,127,34,128,129,130,131,132],"MASH","metabolic flux analysis","stable isotope tracer","bariatric surgery","Roux-en-Y gastric bypass","liver fat","magnetic resonance elastography","citric acid cycle","gluconeogenesis","free fatty acid turnover","2026-08-07",{"date":66,"type":39},{"date":41,"type":22},{"date":137,"type":22},"2060-01-01",{"name":45,"class":46},{"id":140,"slug":141,"hasResults":12,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":147,"enrollmentInfo":148,"targetDuration":4,"studyType":23,"phases":150,"briefSummary":151,"conditions":152,"keywords":155,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":47},"100650334","comparison-of-hormonal-response-to-a-mixed-meal-tolerance-test-after-laparoscopic-roux-en-y-gastric-bypass-versus-laparoscopic-sleeve-gastrectomy-with-duodenojejunal-bypass-in-patients-with-super-morbid-obesity-100650334","NCT07747779","Comparison of Hormonal Response to a Mixed-Meal Tolerance Test After Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy With Duodenojejunal Bypass in Patients With Super Morbid Obesity","Comparison of Hormonal Response to a Mixed-Meal Tolerance Test After Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy With Duodenojejunal Bypass in Patients With Super Morbid Obesity: A Prospective Single-Center Non-Inferiority Randomized Clinical Trial","CU BYPASS-DJB","Inclusion Criteria:\n\n* Patients with an indication for bariatric surgery\n* BMI 50-60 kg\u002Fm2\n* Patients who are motivated to lose weight but have not achieved successful weight reduction despite optimal medical therapy and exercise under physician supervision\n\nExclusion Criteria:\n\n* Patients with diabetes mellitus\n* Patients with severe comorbid conditions that contraindicate surgery, such as advanced heart disease or chronic kidney failure\n* Patients with a history of previous bariatric surgery\n* Patients with gastroesophageal reflux disease refractory to medical therapy, large hiatal hernia, or endoscopic findings of reflux esophagitis grade C or D, or Barrett esophagus\n* Patients with psychiatric disorders that impair eating behavior control\n* Patients with a history of pancreatitis, pancreatic disease, or inflammatory bowel disease\n* Patients who have used steroids or GLP-1 receptor agonists within the past 2 months","60 Years",{"count":149,"type":22},32,[25],"Obesity is a major global health problem. Bariatric surgery is the most effective treatment, leading to substantial weight loss and improvement in obesity-related comorbidities. The most commonly performed procedures are Laparoscopic Roux-en-Y gastric bypass (LRYGB) and Laparoscopic sleeve gastrectomy (LSG). LRYGB is typically selected for patients with a BMI exceeding 50 kg\u002Fm2. Recently, LSG with duodenojejunal bypass (LSG-DJB) has been introduced. To date, no randomized controlled trial has compared LRYGB and LSG-DJB in patients with super morbid obesity, particularly regarding postoperative hormonal responses. This study aims to address this gap. If LSG-DJB results in a lower incidence of post-bariatric hypoglycemia than LRYGB, it would support its clinical benefit. Evaluation of GLP-1, GIP, glucagon, and insulin responses will clarify mechanisms underlying weight loss and postprandial glycemic changes.",[29,153,154],"Hormonal Response","Post Bariatric Hypoglycemia",[29,153,156],"Post bariatric hypoglycemia","2026-08-04",{"date":159,"type":39},"2026-08-06",{"date":161,"type":39},"2024-08-08",{"date":163,"type":22},"2027-07-31",{"name":165,"class":46},"Chulalongkorn University",{"id":167,"slug":168,"hasResults":12,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":174,"enrollmentInfo":175,"targetDuration":4,"studyType":23,"phases":177,"briefSummary":178,"conditions":179,"keywords":183,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":47},"100650369","rosuvastatin-and-losartan-pharmacokinetics-after-bariatric-surgery-100650369","NCT07748273","Rosuvastatin and Losartan Pharmacokinetics After Bariatric Surgery","Comparative Evaluation of Rosuvastatin and Losartan Pharmacokinetics and the Associations Between Gut Microbiota Alterations and Changes in Systemic Drug Exposure in Patients Undergoing Roux-en-Y Gastric Bypass or Sleeve Gastrectomy","BARI-PK","Inclusion Criteria:\n\n* Adults aged 18 to 65 years;\n* Formal clinical indication for RYGB or sleeve gastrectomy after multidisciplinary assessment;\n* Bariatric surgery scheduled and no previous bariatric procedure;\n* Able to understand the study and provide written informed consent.\n\nExclusion Criteria:\n\n* Moderate or severe hepatic impairment, liver enzymes greater than 3 times the upper limit of normal, or Child-Pugh class B or C.\n* Estimated glomerular filtration rate below 30 mL\u002Fmin\u002F1.73 m².\n* Concomitant use of drugs that substantially affect rosuvastatin pharmacokinetics and cannot be temporarily discontinued, including cyclosporine, gemfibrozil, or potent OATP1B1\u002FBCRP or CYP2C9 inhibitors.\n* Systemic antibiotic use within 3 months or probiotic, prebiotic, or synbiotic use within 4 weeks before sampling.\n* Continuous current rosuvastatin or other statin therapy unless medically discontinued with an adequate washout period under physician supervision.\n* Clinically relevant baseline hypotension, significant hyperkalemia, renal impairment, or another condition that makes a losartan test dose unsafe.\n* Severe postoperative complication preventing oral dosing, including active gastrointestinal leak, intractable vomiting, or severe anastomotic stenosis.\n* Pregnancy. Participants of childbearing potential undergo routine preoperative beta-hCG testing.","65 Years",{"count":176,"type":22},60,[25],"This prospective, open-label, non-randomized pharmacokinetic study will evaluate how Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy affect systemic exposure to single oral test doses of rosuvastatin and losartan. Sixty adults scheduled for bariatric surgery will enter one of two parallel groups according to the clinically selected operation (30 RYGB and 30 sleeve gastrectomy). Each participant will receive rosuvastatin 10 mg and losartan 25 mg once within 30 days before surgery and again approximately 12 weeks after surgery. Plasma samples collected before dosing and at 1.5 and 4 hours after dosing will be used with maximum a posteriori Bayesian estimation to estimate individual pharmacokinetic parameters. In the 30-participant RYGB group only, paired stool samples will be used to explore gut microbiota and untargeted fecal metabolomic changes. The primary objective is to compare within-participant changes and between-procedure differences in drug exposure after bariatric surgery.",[180,29,181,182],"Obesity & Overweight","Pharmacokinetics After Oral Intake","Drug Absorption",[127,34,184,185,186,187,188,189],"rosuvastatin","losartan","E-3174","gut microbiota","metabolomics","systemic exposure","2026-08-03",{"date":192,"type":39},"2026-08-05",{"date":194,"type":22},"2026-08-02",{"date":196,"type":22},"2027-05-15",{"name":198,"class":46},"Hospital das Clínicas de Ribeirão Preto",{"id":200,"slug":201,"hasResults":12,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":23,"phases":209,"briefSummary":211,"conditions":212,"keywords":213,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":222,"startDateStruct":223,"completionDateStruct":224,"leadSponsor":226,"locationsCount":47},"100650337","phase-4-swap-anesthetic-versus-continuous-desflurane-in-adults-undergoing-bariatric-surgery-100650337","NCT07748247","Swap Anesthetic Versus Continuous Desflurane in Adults Undergoing Bariatric Surgery","Desflurane Versus Sevoflurane-Desflurane Swap in Adults Undergoing Bariatric Surgery: A Randomized Non-Inferiority Trial on Extubation Time","SWAP","Inclusion Criteria:\n\n* Age 18 years or older.\n* Scheduled for elective laparoscopic gastric bypass surgery.\n* Body mass index between 30 and 50 kg\u002Fm².\n* American Society of Anesthesiologists physical status II or III.\n* Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Surgical procedure lasting less than 2 hours.\n* Body mass index greater than 50 kg\u002Fm².\n* Significant cardiac disease.\n* Moderate or severe obstructive respiratory disease, including uncontrolled asthma or chronic obstructive pulmonary disease.\n* Pregnancy or breastfeeding.\n* Known allergy or contraindication to medications used during the intraoperative period.\n* Personal or family history of malignant hyperthermia.\n* Active illicit drug use or substance dependence.\n* Advanced chronic kidney disease, defined as an estimated glomerular filtration rate below 60 mL\u002Fmin.\n* Myasthenia gravis or another neuromuscular junction disorder.\n* Severe cognitive or psychiatric disorder.\n* Refusal to participate or withdrawal of informed consent at any time.",{"count":208,"type":22},82,[210],"PHASE4","This randomized, parallel-group, non-inferiority clinical trial aims to evaluate whether an anesthetic swap strategy consisting of sevoflurane followed by desflurane 30 minutes before the end of surgery is non-inferior to continuous desflurane anesthesia with respect to extubation time in adults undergoing elective laparoscopic bariatric surgery. Secondary outcomes include time to achieve a Patient State Index (PSi) greater than 80, time to achieve an Aldrete score of at least 8, incidence of postoperative nausea and vomiting, post-anesthesia care unit length of stay, and desflurane-related costs.",[121,29],[214,215,216,29,217,121,218,219,220,221],"Desflurane","Sevoflurane","General Anesthesia","Extubation Time","Laparoscopic Gastric Bypass","Randomized Trial","Non-Inferiority Trial","Patient State Index",{"date":192,"type":39},{"date":190,"type":22},{"date":225,"type":22},"2027-04",{"name":227,"class":46},"Clínica Dávila",{"id":229,"slug":230,"hasResults":12,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":234,"eligibilityCriteria":235,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":23,"phases":238,"briefSummary":239,"conditions":240,"keywords":243,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":254,"completionDateStruct":255,"leadSponsor":257,"locationsCount":47},"100648967","transit-bipartition-after-sleeve-gastrectomy-100648967","NCT07728682","Transit Bipartition After Sleeve Gastrectomy","Clinical, Metabolic, and Physiological Evaluation of Conversion From Sleeve Gastrectomy to Intestinal Transit Bipartition","BTT-SLEEVE","Inclusion Criteria:\n\n* Age 18 years or older;\n* Previous sleeve gastrectomy for the treatment of obesity;\n* Follow-up at the HCRP gastrosurgery\u002Fbariatric surgery outpatient clinic through 2026;\n* Clinical evaluation supporting revisional conversion to intestinal transit bipartition;\n* Willingness to undergo the new surgical procedure and provide written informed consent.\n\nExclusion Criteria:\n\n* Liver cirrhosis;\n* Absence of willingness to undergo a new surgical procedure.",{"count":237,"type":22},40,[25],"This prospective, single-center study will evaluate adults undergoing revisional conversion from sleeve gastrectomy to intestinal transit bipartition. Forty participants will complete clinical, endoscopic, physiological, metabolic, hormonal, imaging, and stool assessments before surgery and during follow-up. The primary outcome is the within-participant change in solid-meal gastric emptying half-time (T½), measured by standardized scintigraphy from baseline to 6 months. Secondary and exploratory outcomes include reflux symptoms, DeMeester score and acid exposure, route-specific gastric transit, GLP-1 and ghrelin responses, glucose metabolism, fecal elastase, gut microbiota, body-weight trajectory, comorbidities, gastroileal anastomotic caliber, and safety.",[180,241,242,29],"Gastroesophageal Reflux (GERD)","Weight Recurrence",[34,244,245,246,247,248,249,250,251],"transit bipartition","gastric emptying","scintyigraphy","T1\u002F2","DeMeester score","gastroileal anastomosis","GLP-1","fecal elastase","2026-07-30",{"date":190,"type":39},{"date":194,"type":22},{"date":256,"type":22},"2027-09-30",{"name":198,"class":46},{"id":259,"slug":260,"hasResults":12,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":174,"enrollmentInfo":266,"targetDuration":4,"studyType":23,"phases":268,"briefSummary":269,"conditions":270,"keywords":272,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":47},"100628084","digital-follow-up-and-nursing-education-in-bariatric-surgery-patients-100628084","NCT07457034","Digital Follow-Up and Nursing Education in Bariatric Surgery Patients","The Effect of the Use of a PHP-MySQL Database-Based Follow-Up System and Nursing Education on Quality of Life in Patients Undergoing Bariatric Surgery","DigiBarQoL","Inclusion Criteria:\n\n* Adults aged 18-65 years Undergoing bariatric surgery Eligible for physical activity participation according to the International Physical Activity Questionnaire (IPAQ) Able to use the PHP-MySQL based digital follow-up system Willing to participate and provide written informed consent\n\nExclusion Criteria:\n\n* Severe cardiopulmonary disease or any medical condition that contraindicates exercise Uncontrolled hypertension or uncontrolled diabetes Severe musculoskeletal limitations preventing participation in the exercise program Severe psychiatric disorder impairing compliance or follow-up Participation in another interventional study during the study period Refusal or inability to provide informed consent",{"count":267,"type":22},52,[25],"This randomized controlled experimental study aims to evaluate the effect of a PHP-MySQL database-based digital follow-up system combined with structured nursing education on quality of life, body mass index (BMI), and exercise habits in patients undergoing bariatric surgery. Although bariatric surgery is an effective treatment for morbid obesity, long-term success depends largely on adherence to lifestyle modifications, including regular physical activity and sustained behavioral change.\n\nParticipants will be randomly assigned to either an intervention group or a control group. The intervention group will receive structured nursing education along with an 8-week digitally monitored exercise program starting at postoperative month four. The control group will receive standard postoperative care. Outcomes will be assessed using the Moorehead-Ardelt Quality of Life Questionnaire II (MA-II), BMI measurements, and the International Physical Activity Questionnaire (IPAQ). The study aims to provide evidence for integrating digital health technologies and structured nursing interventions into postoperative bariatric care.",[271,29],"Obesity (BMI > 35)",[126,273,274,275,276,277,278,279],"obesity","nursing education","digital health","exercise program","Quality of Life","Physical Activity","Randomized Controlled Trial","2026-07-26",{"date":282,"type":39},"2026-07-28",{"date":284,"type":39},"2026-03-07",{"date":286,"type":22},"2026-12-31",{"name":288,"class":46},"Okan University",{"id":290,"slug":291,"hasResults":12,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":174,"enrollmentInfo":296,"targetDuration":4,"studyType":298,"phases":4,"briefSummary":299,"conditions":300,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":47},"100648093","sarcopenia-indicators-after-bariatric-surgery-100648093","NCT07717333","Sarcopenia Indicators After Bariatric Surgery","Longitudinal Evaluation Of Sarkopenia-Related Parameters After Bariatric Surgery","Inclusion Criteria:\n\n* Adults aged 18 years and older\n* Patients scheduled to undergo bariatric surgery\n* Ability to participate in physical performance tests\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Presence of neurological or musculoskeletal disorders affecting muscle strength or physical performance\n* Severe cardiopulmonary disease limiting physical activity\n* Active malignancy\n* Pregnancy\n* Inability to complete study assessments\n* Refusal to participate in the study",{"count":297,"type":22},80,"OBSERVATIONAL","This prospective observational study aims to evaluate longitudinal changes in sarcopenia-related parameters in patients undergoing bariatric surgery. Obesity and rapid weight loss following bariatric surgery may lead to changes in muscle mass, muscle strength, and physical performance, which are important components of sarcopenia.\n\nParticipants will be evaluated before bariatric surgery and during postoperative follow-up visits. Muscle thickness will be assessed using ultrasonography of the femoral muscles. Muscle strength and physical performance will be evaluated using handgrip strength, the 5-meter walk test, and the five-times sit-to-stand test.\n\nThe study aims to investigate the effects of bariatric surgery on muscle function and physical performance over time and to contribute to the early identification of sarcopenia risk in this patient population.",[121,301,29],"Sarcopenia","2026-07-16",{"date":304,"type":39},"2026-07-21",{"date":306,"type":39},"2026-04-10",{"date":308,"type":22},"2027-06-30",{"name":310,"class":46},"Hatice Zehra FERHATLAR",{"id":312,"slug":313,"hasResults":12,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":4,"eligibilityCriteria":317,"healthyVolunteers":318,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":319,"targetDuration":4,"studyType":298,"phases":4,"briefSummary":321,"conditions":322,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":327,"startDateStruct":329,"completionDateStruct":330,"leadSponsor":332,"locationsCount":4},"100645545","abcg8-ugt1a1-and-gallstone-disease-after-bariatric-surgery-100645545","NCT07702630","ABCG8, UGT1A1 and Gallstone Disease After Bariatric Surgery","ABCG8, UGT1A1 and Gallstone Disease After Bariatric Surgery: A Genetic Study","Inclusion Criteria:\n\n* Bariatric surgery\n\nExclusion Criteria:\n\n* Gallstone disease or cholecystectomy prior to bariatric surgery",true,{"count":320,"type":22},270,"The goal of this observational genetic case-control study is to learn whether two specific genetic variants in ABCG8 and UGT1A1 are associated with gallstone disease after bariatric surgery. The study includes adults who have previously undergone bariatric surgery.\n\nThe main questions it aims to answer are whether the ABCG8 D19H variant and the UGT1A1 rs6742078 variant are associated with an increased risk of gallstone disease requiring cholecystectomy after bariatric surgery.\n\nResearchers will compare patients who underwent bariatric surgery and later had their gallbladder removed because of gallstone disease with patients who underwent bariatric surgery but did not develop gallstone disease or undergo cholecystectomy during follow-up.\n\nParticipants will provide one blood sample for targeted genetic analysis and complete questionnaires about health, previous surgery, medication use, family history, and gastrointestinal quality of life. Relevant clinical information will also be collected from medical records.",[323,29,324,325,326],"Gallstone Disease","Metabolic Surgery","Cholecystectomy","Genetics",{"date":328,"type":39},"2026-07-17",{"date":41,"type":22},{"date":331,"type":22},"2029-03-01",{"name":333,"class":46},"Esbjerg Hospital - University Hospital of Southern Denmark",{"id":335,"slug":336,"hasResults":12,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":340,"eligibilityCriteria":341,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":174,"enrollmentInfo":342,"targetDuration":4,"studyType":23,"phases":344,"briefSummary":345,"conditions":346,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":103},"100576319","mechanistic-and-clinical-outcomes-of-a-surgical-innovation-aimed-at-minimizing-gerd-associated-with-vsg-innovate-vsg-100576319","NCT06783751","Mechanistic and Clinical Outcomes of a Surgical Innovation Aimed at Minimizing GERD Associated With VSG (INNOVATE-VSG)","Mechanistic and Clinical Outcomes of a Surgical Innovation Aimed at Minimizing GERD Associated With Vertical Sleeve Gastrectomy (INNOVATE-VSG)","INNOVATE-VSG","Inclusion Criteria:\n\n1. Male and female subjects aged 18-65 years\n2. Body mass index (BMI) 35-55 kg\u002Fm2\n3. Must meet the BMI criteria before and after 6 months of nonsurgical weight management\n4. Presence of GERD defined for this trial as acid exposure time (AET) of 4.9% or above as assessed with the Bravo pH test.\n5. Have health insurance which pays for the costs of bariatric surgery and standard medical care before and after surgery\n6. Women of childbearing potential must be using appropriate contraception to avoid pregnancy throughout the study, and must have a negative pregnancy test at study entry and prior to surgery\n7. Must be able to provide written informed consent\n\nExclusion Criteria:\n\n1. Hiatal hernia \\>2cm (defined as maximum axial height from end of the esophagus to diaphragm by any study including upper endoscopy esophagram and or at the time of surgery)\n2. Evidence of clinically significant major esophageal motility disorder as determined by the site primary investigator\n3. Severe gastroparesis\n4. Previous bariatric or anti-reflux procedure\n5. Barrett's esophagus\n6. Subjects requiring mesh treatment at time of procedure\n7. Severe heart (e.g., severe heart failure, unstable coronary artery disease), or end-stage lung disease as determined by the site primary investigator\n8. Subjects with pacemakers, implantable defibrillators, neurostimulators\n9. Portal hypertension or cirrhosis\n10. Chronic pancreatitis\n11. Active cancer treatment\n12. Inability to tolerate general anesthesia\n13. Uncontrollable coagulopathy\n14. Significant and uncontrolled inflammatory bowel disease\n15. Severe and\u002For uncontrolled psychiatric disorder (including psychosis, bipolar disorder) as determined during standard pre-surgery psychiatric screening at the site.\n16. Suicidal ideation or unstable\u002Funtreated major depressive disorder within the past year\n17. Alcohol or substance use disorder within the past year.\n18. Pregnant or breastfeeding or planning pregnancy in the coming 24 months\n19. Diminished intellectual capacity to consent or follow pre- and post-surgery instructions\n20. History of, or any current health condition that, in the opinion of the PI, would make the subject ineligible for sleeve gastrectomy, or put the subject at risk by participation in the study.",{"count":343,"type":22},44,[25],"This is a two-site randomized clinical trial aiming to test whether a modified investigational bariatric surgical procedure can improve gastroesophageal reflux disease (GERD) after sleeve gastrectomy.",[121,29,90,347],"Gastroesophageal Reflux Disease","2026-07-13",{"date":350,"type":39},"2026-07-14",{"date":352,"type":39},"2025-03-21",{"date":354,"type":22},"2028-07-01",{"name":356,"class":46},"University of California, Irvine",{"id":358,"slug":359,"hasResults":12,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":363,"eligibilityCriteria":364,"healthyVolunteers":12,"sex":17,"minAge":365,"maxAge":366,"enrollmentInfo":367,"targetDuration":4,"studyType":23,"phases":368,"briefSummary":370,"conditions":371,"keywords":376,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":47},"100560330","phase-1-physiologic-response-to-bariatric-surgery-and-the-impact-of-adjunct-semaglutide-in-adolescents-100560330","NCT06575738","Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents","Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide - in Adolescents (the PRESSURE Trial)","PRESSURE","Observation Phase\n\nInclusion Criteria:\n\n* Signed and dated informed consent form\n* Willingness to comply with all study procedures and availability for the duration of the study\n* Male or female biological sex, age 12 through 24 years\n* In the preoperative pathway for vertical sleeve gastrectomy\n\nExclusion Criteria:\n\n* Planned Roux-en-Y gastric bypass\n* Hypothalamic obesity\n* Type 2 Diabetes\n* Current use of oral glucocorticoids (i.e. within 10 days of baseline visit)\n* Current use of insulin\n\nIntervention\u002FTreatment Phase\n\nInclusion Criteria:\n\n* Signed and dated informed consent form\n* Status post vertical sleeve gastrectomy\n* Male or female biological sex, age 12 through 24 years\n* Meeting minimum nutrition goals\n* Obesity: age 12-17 years: BMI ≥95th%ile for age\u002Fsex \\| age 18-24 years: BMI ≥ 30kg\u002Fm\\^2\n* If entering the Intervention phase from the Observational phase: ≤22% BMI loss at 6-24 months postop\n* If entering the Intervention phase from the existing patient pool: ≤22% BMI loss at 6-24 months postop\n\nExclusion Criteria:\n\n* Surgically correctable cause of suboptimal postoperative weight loss\n* Known hypersensitivity to any component of semaglutide\n* Personal or family history of medullary thyroid carcinoma\n* Personal history of multiple endocrine neoplasia type 2\n* Hypothalamic Obesity\n* Type 2 Diabetes\n* History of pancreatitis\n* Uncontrolled hypertension\n* Clinically significant arrhythmia or heart disease that could be exacerbated by increased heart rate\n* Malignant neoplasm within the last 5 years\n* Untreated thyroid disorder\n* Tanner Stage 1\n* Baseline alanine transaminase (ALT) or aspartate aminotransferase (AST) ≥ 5x upper limit of normal\n* Baseline Creatinine \\>1.2mg\u002FdL\n* Active treatment for bulimia nervosa\n* Active major psychiatric disorder limiting informed consent\n* Suicidal ideation of type 4 or 5 on Columbia-Suicide Severity Rating Scale (C-SSRS)\n* Intentional self-harm within the previous 1 month\n* Severe unmanaged depression, defined by Center for Epidemiological Studies Depression (CESD) score of 26 or greater and by clinical evaluation\n* Recent change to concomitant medications for hypertension, dyslipidemia, depression or anxiety (\\\u003C4 weeks prior to enrollment)\n* Use of oral glucocorticoids (within 10 days of baseline visit)\n* Use of metformin (within 3 months of baseline visit)\n* Use of insulin secretagogues (within 4 half-lives of the medication of baseline visit)\n* Current use of insulin\n* Use of anti-obesity medications (within 4 half-lives of the medication of baseline visit)\n* Current pregnancy\n* For females of reproductive potential: Plan to become pregnant in the next 8 months\n* For females of reproductive potential: Not on contraception (i.e. two forms of birth control for example oral birth control pills and condoms) for at least 1 month prior to enrollment and agreement to use these during study participation and for an additional 8 weeks after the final dose of study medication","12 Years","24 Years",{"count":237,"type":22},[369],"PHASE1","The study plans to learn more about what happens to the body after bariatric surgery in people 12 to 24 years old. The study aims to understand why people respond differently to bariatric surgery and how to define success beyond weight loss alone. The study also plans to learn more about whether a medication (semaglutide or tirzepatide) can help people 12 to 24 years old who, between 6 and 24 months after bariatric surgery, have not lost as much weight as expected.",[121,372,373,374,29,375],"Adolescent Obesity","Body-Weight Trajectory","Weight Loss Trajectory","Anti-obesity Agents",[121,377,29,378,379,380],"Anti-obesity medication","Bariatric Surgery Post Operative Outcomes","Semaglutide","Sleeve gastrectomy",{"date":382,"type":39},"2026-07-15",{"date":384,"type":39},"2024-10-11",{"date":386,"type":22},"2027-10-01",{"name":388,"class":46},"University of Colorado, Denver",{"id":390,"slug":391,"hasResults":12,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":396,"targetDuration":4,"studyType":23,"phases":398,"briefSummary":399,"conditions":400,"keywords":403,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":412,"lastUpdatePostDateStruct":413,"startDateStruct":415,"completionDateStruct":417,"leadSponsor":419,"locationsCount":47},"100646879","dramatherapy-for-psychological-and-social-well-being-in-obesity-and-bariatric-care-100646879","NCT07685483","Dramatherapy for Psychological and Social Well-Being in Obesity and Bariatric Care","Effect of Dramatherapy Combined With Adapted Physical Activity on Psychological and Social Well-Being in Patients With Obesity and Eating Disorders in Medical and Bariatric Care: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 18 years or older.\n* Body mass index (BMI) ≥ 40 kg\u002Fm², or BMI ≥ 35 kg\u002Fm² with obesity-related comorbidities, or BMI ≥ 30 kg\u002Fm² with associated eating disorders or problematic eating behaviors.\n* Enrollment in a medical or bariatric care pathway at the Institut de l'Obésité, Clinique ELSAN Saint-Omer, including a therapeutic education program with adapted physical activity.\n* Availability and willingness to complete the planned study procedures and follow-up assessments.\n* Written informed consent provided after complete information about the study.\n* Affiliation to a social security system.\n\nExclusion Criteria:\n\n* Major medical contraindications to adapted physical activity or group sessions, including unstable cardiovascular disease or severe non-compensable locomotor limitations.\n* Severe psychiatric disorders or severe unstable eating disorders contraindicating bariatric surgery or preventing adequate participation in group sessions.\n* Major cognitive impairment or neuropsychological disorders preventing understanding of instructions or completion of assessments.\n* Unstable medical treatment or recent therapeutic modification likely to significantly affect body weight, fatigability, or mental health.\n* Inability to complete the full study protocol, including prolonged unavailability or planned relocation outside the region.\n* Refusal or inability to provide informed consent.\n* Major logistical barriers preventing access to the intervention site without feasible alternative arrangements.\n* Participation in a structured adapted physical activity program within the 3 months preceding inclusion.",{"count":397,"type":22},250,[25],"Obesity is currently a major public health challenge in France, particularly in the Hauts-de-France region, where prevalence exceeds 20% of the adult population. Bariatric surgery has considerably increased over the last two decades and is now recognized as an effective therapeutic option within a multidisciplinary care pathway. However, many patients continue to experience difficulties related to body image, emotional regulation, problematic eating behaviors, and long-term adherence to adapted physical activity (APA), which may limit the sustainability of treatment benefits. International literature highlights the importance of integrating psychological and psychosocial support alongside medical, nutritional, and physical interventions.\n\nThis monocentric randomized controlled trial aims to evaluate the effects of adding dramatherapy (DT) to a standardized APA program in adult patients with obesity enrolled in medical or bariatric care pathways at the Institut de l'Obésité of Clinique ELSAN Saint-Omer (France). Participants will be randomized to receive either standard APA alone or APA combined with DT. The intervention is designed to improve emotional expression, body perception, self-confidence, psychosocial well-being, and long-term adherence to care. Dramatherapy sessions will include theatrical expression, role play, improvisation, relaxation, and body-oriented creative exercises adapted to patients with obesity.\n\nThe primary objective is to evaluate the effect of DT on quality of life at the end of care, compared with APA alone, using the French version of the EQVOD questionnaire. Secondary objectives include the evaluation of eating behaviors and problematic eating regulation (TFEQ-R18, SCOFF), body image and body-related quality of life (BIQLI), self-efficacy (GSES), anxiety and depressive symptoms (BDI-II), adherence to APA programs, and anthropometric parameters such as body mass index, abdominal circumference, and body composition. Assessments will be conducted at baseline, at the end of the intervention, and at 6- and 12-month follow-up.\n\nThe study also includes a complementary qualitative component based on semi-structured interviews, ethnographic observation, body mapping, and identity boxes in order to explore patients' subjective experiences, psychosocial trajectories, and perceived impact of the intervention. Quantitative and qualitative data will be analyzed using a mixed-methods approach. A total of 250 participants are expected to be included. This study seeks to provide evidence regarding the potential added value of integrating dramatherapy into obesity and bariatric care pathways.",[401,180,402,29],"Obesity (Disorder)","Eating Disorders",[121,402,29,404,405,406,407,408,409,410,411],"Dramatherapy","Art Therapy","Adapted Physical Activity","Body image","Quality of life","Psychosocial Well-Being","Psychosocial intervention","Body Mapping","2026-07-01",{"date":414,"type":39},"2026-07-06",{"date":416,"type":39},"2026-06-30",{"date":418,"type":22},"2029-05",{"name":420,"class":46},"Universite du Littoral Cote d'Opale",{"id":422,"slug":423,"hasResults":12,"nctId":424,"briefTitle":425,"officialTitle":426,"acronym":4,"eligibilityCriteria":427,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":174,"enrollmentInfo":428,"targetDuration":4,"studyType":23,"phases":429,"briefSummary":430,"conditions":431,"keywords":435,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":103},"100644753","time-restricted-eating-after-bariatric-surgery-100644753","NCT07672821","Time-Restricted Eating After Bariatric Surgery","Comparison of Time-Restricted Intermittent Fasting Diet in Individuals With and Without Bariatric Surgery","Inclusion Criteria:\n\n* Adults aged 18-65 years with obesity who have not undergone bariatric surgery\n* Adults aged 18-65 years with obesity who have undergone bariatric surgery and experienced insufficient weight loss (IWL) within 18 months post-surgery, -defined as %EWL \\\u003C50% at 18 months\n* Adults aged 18-65 years with obesity who have undergone bariatric surgery and experienced weight regain (WR), defined as \\>25% increase in %EWL from the lowest recorded weight\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding individuals\n* Acute illness, active infection, or comorbid conditions limiting treatment efficacy and safety, including: cancer, type 1 diabetes, renal or hepatic failure, recent stroke or myocardial infarction, nephrolithiasis, drug or alcohol abuse, eating disorders, severe depression or other psychiatric disorders, inflammatory bowel disease (IBD), neoplasia, arrhythmic heart disease, heart failure, respiratory failure, or corticosteroid therapy\n* Professional athletes",{"count":237,"type":22},[25],"This study aims to compare the effects of time-restricted eating (TRE, 16\u002F8) in adults with obesity who have and have not undergone bariatric surgery (BS). The study will include adults aged 18-65 years: those with obesity who have not undergone BS, and those who have experienced insufficient weight loss (IWL) or weight regain (WR) following BS. Both groups will follow a 16:8 time-restricted eating protocol for 6 weeks, with an 8-hour eating window recommended between 10:00 AM and 6:00 PM, though participants may adjust to other 16-hour fasting windows. Participants will be evaluated before and after the intervention in terms of anthropometric measurements, biochemical parameters, and dietary habits. The study is being conducted at a private hospital in Bursa, Turkey, and is planned to be completed with a total of 40 participants (20 per group).",[180,29,432,433,434],"Weight Regain","Weight Regain Post Bariatric Surgery","Time Restricted Feeding",[436,437,29,121,432,438,439],"Time-Restricted Eating","Intermittent Fasting","Anthropometric Measurements","Nutritional Assessment","2026-06-26",{"date":442,"type":39},"2026-06-29",{"date":444,"type":39},"2025-07-12",{"date":446,"type":22},"2026-07-12",{"name":448,"class":46},"Medipol University",{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":4,"eligibilityCriteria":455,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":456,"enrollmentInfo":457,"targetDuration":4,"studyType":23,"phases":458,"briefSummary":459,"conditions":460,"keywords":463,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":47},"100643847","3d-reconstruction-vr-and-machine-learning-in-body-image-in-bariatrics-100643847","NCT07668492","3D Reconstruction, VR and Machine Learning in Body Image in Bariatrics","The Use of 3D Reconstruction, Virtual Reality, and Machine Learning in Addressing Body Image in Bariatric Metabolic Surgery.","Inclusion Criteria:\n\n* Tier 4 bariatric group\n* On waiting list for bariatric metabolic surgery\n* Able to stand unaided for at least 5 minutes\n\nExclusion Criteria:\n\n* Anyone who cannot provide informed consent\n* Anyone who is involved in current research or has recently been involved in any research prior to recruitment.","75 Years",{"count":297,"type":22},[25],"Studies have shown that following bariatric metabolic surgery (BMS), patients continue to experience dissatisfaction with their new body image and identity). The reason for this is poorly understood but negative body image perception after surgery is linked to poor psychological and clinical outcomes. Our pilot study looking at the acceptability and feasibility of 3D reconstruction and virtual reality (VR) in addressing body image in BMS found that participants felt better informed about how their body will change following significant weight loss and agreed this novel intervention would be beneficial in helping patients adjust to changes in their body after BMS.\n\nThe investigators propose a randomised control trial comparing group body image counselling and group body image counselling with 3D reconstruction and VR in addressing body image in BMS. The study aims to enrol 80 participants from the Tier 4 bariatric group at St Mary's Hospital and Chelsea \\& Westminster Hospital. After consent, participants will be divided into two groups: the control group will receive traditional group body image counselling, and the intervention group will receive the same counselling supplemented with VR and 3D reconstructed images depicting 15% and 25% total less body weight. Both groups will undergo four sessions over six months.\n\nThe investigators will collect data including body measurements and 3D images of the participant in their underwear using a secure password protected device at baseline and follow participants at 3, 6, 9, 12, 18, 24, and 36 months post-BMS. Patient reported outcomes will be assessed through patient-reported questionnaires.\n\nThis trial seeks to determine if integrating 3D reconstruction and VR technology into body image counselling can provide better support for patients adjusting to body image changes post-BMS, potentially leading to improved psychological and clinical outcomes.",[401,461,462,29],"Body Image","Mental Health",[464,465,461,466,467],"3D Reconstruction","Virtual Reality","Machine Learning","Bariatric Metabolic Surgery","2026-06-19",{"date":470,"type":39},"2026-06-25",{"date":472,"type":22},"2026-06",{"date":474,"type":22},"2030-03",{"name":476,"class":46},"Imperial College London",{"id":478,"slug":479,"hasResults":12,"nctId":480,"briefTitle":481,"officialTitle":481,"acronym":482,"eligibilityCriteria":483,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":484,"targetDuration":4,"studyType":23,"phases":486,"briefSummary":487,"conditions":488,"keywords":495,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":497,"lastUpdatePostDateStruct":498,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":504,"locationsCount":47},"100589244","identification-of-pre-surgical-phenotypic-indicators-predictive-of-quality-of-life-trajectories-in-obese-patients-following-bariatric-surgery-100589244","NCT06951893","Identification of Pre-surgical Phenotypic Indicators Predictive of Quality of Life Trajectories in Obese Patients Following Bariatric Surgery","PHENOBEQOL73","Inclusion Criteria:\n\n* patient \\> 18years old\n* Integrated into the GEROM73 surgical program and starting the intra-hospital program\n\nExclusion Criteria:\n\n* Patients in a state of psychiatric decompensation\n* Patients with cognitive disorders\n* Patients with difficulties understanding the French language, spoken or written\n* Pregnant, parturient, or breastfeeding women",{"count":485,"type":22},165,[25],"This study aims to identify pre-operative phenotypic determinants predictive of quality of life trajectories in post-bariatric surgery patients. In addition, this study will have as a secondary objective the highlighting of a potential link between post-surgery quality of life trajectories and those of anxiety\u002Fdepression scores, eating behaviors and body mass indices.\n\nThis study will be conducted during the usual care of patients undergoing the GEROM73 program, lasting a total of 30 months.\n\nThe GEROM73 program includes care for the six months preceding bariatric surgery and the 24 months following surgery. This program supports patients throughout their bariatric care..\n\nThroughout the GEROM73 program, patients will complete questionnaires on anxiety, depression, eating disorders, Impact of Weight on Quality Of Life.\n\nPatients' weight, body mass index and body schema will also be measured throughout the GEROM program.",[489,490,29,491,492,493,494],"Obesity, Morbid","Obesity and Overweight","Bariatric Surgery Patients","Bariatric Surgery Patient","Bariatric Surgery (Sleeve Gastrectomy )","Bypass, Gastric",[496,482],"GEROM73","2026-06-09",{"date":499,"type":39},"2026-06-10",{"date":501,"type":39},"2025-06-17",{"date":503,"type":22},"2030-09-09",{"name":505,"class":46},"Centre Hospitalier Metropole Savoie",{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":512,"eligibilityCriteria":513,"healthyVolunteers":12,"sex":17,"minAge":514,"maxAge":515,"enrollmentInfo":516,"targetDuration":4,"studyType":298,"phases":4,"briefSummary":517,"conditions":518,"keywords":522,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":534,"completionDateStruct":535,"leadSponsor":537,"locationsCount":47},"100643167","evaluation-of-metabolic-parameters-intestinal-permeability-and-gastrointestinal-symptoms-after-bariatric-surgery-in-body-weight-management-100643167","NCT07643376","Evaluation of Metabolic Parameters, Intestinal Permeability and Gastrointestinal Symptoms After Bariatric Surgery in Body Weight Management","Evaluation of Postoperative Metabolic Parameters, Intestinal Permeability and Gastrointestinal Symptoms in Body Weight Management After Laparoscopic Sleeve Gastrectomy","METABAR","Inclusion Criteria:\n\n* Underwent Laparoscopic Sleeve Gastrectomy (LSG) within the last 1 month\n* Aged between 19-50 years\n* BMI ≥40 kg\u002Fm² or BMI ≥35 kg\u002Fm² with obesity-related comorbidities\n* Signed informed consent form\n* Non-smoker and non-alcohol dependent\n\nExclusion Criteria:\n\n* Did not undergo or is not planned to undergo LSG\n* Outside the age range of 19-50 years\n* Did not sign the informed consent form\n* BMI \\\u003C40 kg\u002Fm² or BMI \\\u003C35 kg\u002Fm² without obesity-related comorbidities\n* Smoker or alcohol dependent\n* Has an inflammatory disease\n* Currently using probiotics, antibiotics, or fiber supplements\n* Has a psychiatric disorder","19 Years","50 Years",{"count":237,"type":22},"This study aims to evaluate the changes in metabolic parameters, intestinal permeability, and gastrointestinal symptoms in individuals who have undergone bariatric surgery (Laparoscopic Sleeve Gastrectomy - LSG) for obesity treatment.\n\nObesity is a chronic disease associated with serious health complications including type 2 diabetes, hypertension, cardiovascular disease, and metabolic disorders. Bariatric surgery is currently the most effective treatment method for morbid obesity. However, monitoring patients after surgery in terms of metabolic health, gut permeability, and gastrointestinal symptoms is crucial for long-term success.\n\nIn this study, 40 volunteers (aged 19-50) who have undergone LSG surgery within the last month will be followed for 6 months. At the beginning of the study and 6 months later, the following will be assessed:\n\n* Metabolic parameters: fasting blood glucose, total cholesterol, triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL), very low-density lipoprotein (VLDL) cholesterol, and insulin levels\n* Intestinal permeability markers: zonulin, secretory immunoglobulin A (IgA), and lipopolysaccharide (LPS) levels\n* Gastrointestinal symptoms: assessed using the Gastrointestinal Symptom Rating Scale (GSRS)\n* Anthropometric measurements: body weight, height, waist and hip circumference, BMI\n* Nutritional intake: 3-day dietary records\n\nThe study will be conducted at Bursa Yıldırım Doruk Hospital, General Surgery Clinic. Results will contribute to understanding the relationship between bariatric surgery and gut health, potentially helping to prevent postoperative complications.",[489,29,519,520,521],"Intestinal Permeability","Gastrointestinal Symptoms","Metabolic Syndrome",[523,524,525,526,527,528,529,530],"Laparoscopic Sleeve Gastrectomy","Zonulin","Secretory IgA","Lipopolysaccharide","GSRS","Body Weight Management","Gut microbiota","Postoperative Metabolic Parameters","2026-06-08",{"date":533,"type":39},"2026-06-11",{"date":412,"type":22},{"date":536,"type":22},"2027-02-01",{"name":538,"class":46},"Toros University",{"id":540,"slug":541,"hasResults":12,"nctId":542,"briefTitle":543,"officialTitle":544,"acronym":545,"eligibilityCriteria":546,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":515,"enrollmentInfo":547,"targetDuration":4,"studyType":298,"phases":4,"briefSummary":548,"conditions":549,"keywords":552,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":561,"startDateStruct":562,"completionDateStruct":563,"leadSponsor":564,"locationsCount":47},"100643754","eating-behavior-nutritional-status-and-appetite-hormones-after-bariatric-surgery-100643754","NCT07636239","Eating Behavior, Nutritional Status and Appetite Hormones After Bariatric Surgery","Evaluation of Changes in Postoperative Eating Behavior Attitudes, Nutritional Status, and Some Hormonal Parameters Regulating Appetite in Surgical Weight Management","BCKYL-YDB","Inclusion Criteria:\n\n* Having undergone Laparoscopic Sleeve Gastrectomy (LSG) within the last month\n* Aged between 18-50 years\n* Signing the informed consent form\n* Having a Body Mass Index (BMI) of 40 kg\u002Fm2 or between 35-40 kg\u002Fm2 with obesity-related comorbidities\n* No diagnosis of depression\n* No eating behavior disorder\n* No psychiatric disorder\n\nExclusion Criteria:\n\n* Not having undergone Laparoscopic Sleeve Gastrectomy (LSG) or not planning to undergo bariatric surgery\n* Not being in the age range of 18-50 years\n* Not signing the informed consent form\n* Having a Body Mass Index (BMI) greater than 40 kg\u002Fm2 or less than 35 kg\u002Fm2 without obesity-related comorbidities\n* Having a diagnosis of depression\n* Having an eating behavior disorder\n* Having a psychiatric disorder",{"count":237,"type":22},"This study aims to evaluate changes in eating behavior attitudes, nutritional status, and appetite-regulating hormonal parameters in individuals who have undergone Laparoscopic Sleeve Gastrectomy (LSG). The study will be conducted at Bursa Yıldırım Doruk Hospital, Department of General Surgery. A total of 40 volunteer participants who underwent LSG within the last month will be included. Participants will be assessed at baseline (shortly after surgery) and at 6-month follow-up. Assessments will include anthropometric measurements (body weight, height, waist and hip circumference, BMI, waist-to-hip ratio), 3-day dietary intake records analyzed using BeBIS 8.2 software, and the Adult Eating Behavior Scale. Biochemical parameters including fasting blood glucose, total cholesterol, triglycerides, HDL, LDL, VLDL cholesterol, and insulin will be obtained from patient files and analyzed using Advia Chemistry 2400 and Advia XPT devices. Additionally, appetite-regulating hormones (ghrelin, GLP-1, PYY) will be analyzed from residual blood samples using the ELISA method with RelAssay Diagnostics kits by Teknogen Bioengineering Laboratory. All data will be compared between baseline and 6-month follow-up to evaluate the impact of bariatric surgery on nutritional and hormonal outcomes.",[121,29,523,550,551],"Eating Behavior","Nutritional Status",[121,29,523,550,553,554,250,555,556,557,558,559],"Nutritional status","Ghrelin","Peptite YY","Appetite hormones","Body mass index","Weight loss","Dietary intake","2026-06-02",{"date":497,"type":39},{"date":412,"type":22},{"date":536,"type":22},{"name":565,"class":46},"Özlem ÖZPAK AKKUŞ",{"id":567,"slug":568,"hasResults":12,"nctId":569,"briefTitle":570,"officialTitle":570,"acronym":4,"eligibilityCriteria":571,"healthyVolunteers":318,"sex":17,"minAge":81,"maxAge":113,"enrollmentInfo":572,"targetDuration":4,"studyType":298,"phases":4,"briefSummary":574,"conditions":575,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":583,"locationsCount":103},"100464287","improvement-in-glycemic-response-after-bariatric-surgery-100464287","NCT05325736","Improvement in Glycemic Response After Bariatric Surgery","Inclusion Criteria:\n\n* candidates of bariatric surgery or cholecystectomy\n* age 18-70\n* male\u002Ffemale\n\nExclusion Criteria:\n\n* previous bariatric surgery\n* type 1 diabetes\n* antibiotic treatment 3 months prior to the study\n* probiotic treatment 3 months prior to the study\n* chronic disease - gastrointestinal disease, malignancy, psychiatric disorder, endocrinologic disorders\n* any pathologic findings during endoscopy\n* participants who will suffer from a post-operation complication",{"count":573,"type":22},120,"decipher the role of microbiota in glycemic response change after bariatric surgery",[29],"2026-05-19",{"date":578,"type":39},"2026-05-20",{"date":580,"type":39},"2021-07-01",{"date":582,"type":22},"2029-07-01",{"name":584,"class":46},"Weizmann Institute of Science",{"id":586,"slug":587,"hasResults":12,"nctId":588,"briefTitle":589,"officialTitle":589,"acronym":4,"eligibilityCriteria":590,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":113,"enrollmentInfo":591,"targetDuration":4,"studyType":23,"phases":593,"briefSummary":594,"conditions":595,"keywords":599,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":602,"lastUpdatePostDateStruct":603,"startDateStruct":604,"completionDateStruct":606,"leadSponsor":608,"locationsCount":47},"100533156","recovering-from-bariatric-surgery-the-effects-of-early-initiated-and-supervised-mobilization-100533156","NCT06222151","Recovering From Bariatric Surgery: the Effects of Early Initiated and Supervised Mobilization","Inclusion Criteria:\n\n* The ability to read and understand the Danish language\n\nExclusion Criteria:\n\n* Preoperative dependence of walking aids\n* Vision impairment\n* Previous syncopes or epilepsy\n* Admission to the intensive care unit after surgery\n* Acute complications during hospital admission\n* Patients are excluded at baseline if they have an oxygen saturation below 90% or a systolic blood pressure above 180 mmHg",{"count":592,"type":22},112,[25],"The aim is to investigate the effect of early initiated and supervised mobilization continued after discharge as management of postoperative pain and recovery following obesity surgery, including patient experiences, pain coping, physical functionality and quality of life.",[596,597,29,598,278],"Postoperative Pain, Acute","Postoperative Pain, Chronic","Mobilization",[600,29,601,278,598],"Pain Coping","Postoperative Pain","2026-05-18",{"date":578,"type":39},{"date":605,"type":39},"2024-04-22",{"date":607,"type":22},"2027-12-26",{"name":333,"class":46},{"id":610,"slug":611,"hasResults":12,"nctId":612,"briefTitle":613,"officialTitle":614,"acronym":4,"eligibilityCriteria":615,"healthyVolunteers":12,"sex":17,"minAge":616,"maxAge":147,"enrollmentInfo":617,"targetDuration":4,"studyType":23,"phases":619,"briefSummary":620,"conditions":621,"keywords":623,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":626,"lastUpdatePostDateStruct":627,"startDateStruct":628,"completionDateStruct":629,"leadSponsor":631,"locationsCount":103},"100636747","effect-of-transcutaneous-electrical-nerve-stimulation-on-podd-in-bariatric-surgery-patients-100636747","NCT07569705","Effect of Transcutaneous Electrical Nerve Stimulation on PODD in Bariatric Surgery Patients","Effect of Transcutaneous Electrical Nerve Stimulation on Postoperative Diaphragmatic Dysfunction in Morbidly Obese Patients Undergoing Bariatric Surgery: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Body mass index \\> 40 kg\u002Fm2\n* ASA II\n\nExclusion Criteria:\n\n* Limited diaphragmatic ultrasound views\n* Patient with pulmonary diseases (COPD, bronchial asthma, and interstitial fibrosis)\n* Patient refusal","20 Years",{"count":618,"type":22},70,[25],"Researchers aim to evaluate impact of transcutaneous electric nerve stimulator on the incidence of postoperative diaphragmatic dysfunction in patients living with obesity undergoing bariatric surgery",[29,622],"Bariatric Surgery Candidate",[624,625],"Bariatric","Diaphragmatic dysfunction","2026-05-17",{"date":578,"type":39},{"date":626,"type":39},{"date":630,"type":22},"2026-08-30",{"name":632,"class":46},"Cairo University",{"id":634,"slug":635,"hasResults":12,"nctId":636,"briefTitle":637,"officialTitle":638,"acronym":639,"eligibilityCriteria":640,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":641,"targetDuration":4,"studyType":23,"phases":643,"briefSummary":644,"conditions":645,"keywords":648,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":653,"lastUpdatePostDateStruct":654,"startDateStruct":655,"completionDateStruct":656,"leadSponsor":658,"locationsCount":47},"100635973","the-oat-trail-the-obesity-anti-coagulation-thromboprophylaxis-trial-100635973","NCT07559643","The OAT Trail: The Obesity Anti-Coagulation Thromboprophylaxis Trial.","A Prospective, Randomised Controlled Trial Comparing Weight-based Tinzaparin Versus Weight-based Enoxaparin for Peri-operative Thromboprophylaxis in Patients Undergoing Bariatric Surgery: Evaluation of Anti-Xa Levels and Clinical Outcomes.","The OAT-RCT","Inclusion Criteria:\n\n* Age ≥18 years\n* BMI ≥40 kg\u002Fm², or BMI ≥35 kg\u002Fm² with at least one obesity-related comorbidity (type 2 diabetes, hypertension, obstructive sleep apnoea, dyslipidaemia, or metabolic dysfunction-associated steatotic liver disease (MASLD))\n* Scheduled to undergo laparoscopic bariatric surgery (sleeve gastrectomy or gastric bypass) at St Vincent's University Hospital, Dublin, Ireland\n* Capacity to provide written informed consent\n\nExclusion Criteria:\n\n* Current therapeutic anticoagulation for any indication Known allergy or hypersensitivity to tinzaparin, enoxaparin, heparin, or any heparin-derived product, including documented heparin-induced thrombocytopaenia (HIT) Any other contraindication to LMWH therapy Severe renal impairment (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²) Known haematological disorder or coagulopathy Pregnancy, breastfeeding, or planning pregnancy during the study period Active major bleeding or high bleeding risk at the discretion of the treating clinician Inability to provide written informed consent Participation in another interventional clinical study within 30 days prior to enrolment",{"count":642,"type":22},180,[25],"Blood clots in the legs or lungs (called venous thromboembolism or VTE) are one of the most serious complications after weight loss surgery. Most blood clots occur after patients go home from hospital, within the first 30 days after surgery. To prevent blood clots, all patients having weight loss surgery receive a daily blood-thinning injection for 21 days after their operation.\n\nTwo blood-thinning injections are currently used at St Vincent's University Hospital for this purpose: enoxaparin (Clexane®) and tinzaparin (Innohep®). Both belong to a group of medicines called low molecular weight heparins (LMWHs). Patients with obesity process these medicines differently to the general population, and previous studies from our hospital have shown that fewer than 53% of patients achieve adequate blood-thinning levels with either injection when measured by a blood test called an anti-Xa level.\n\nPatients will be randomly assigned (like a coin toss) to receive either tinzaparin or enoxaparin for 21 days after their surgery. Both injections are already in routine use at this hospital. A single extra blood sample will be taken on the second day after surgery to measure the anti-Xa level, which tells us whether the injection is providing adequate protection against blood clots. This blood sample will be taken at the same time as routine post-operative blood tests so that no additional blood draws are required.\n\nThe study will also look at rates of blood clots and bleeding events within 30 days of surgery, and will ask patients to complete a short questionnaire at their six-week follow-up appointment about their experience with the injection.",[29,646,647,180],"Anti-Xa Activity","VTE (Venous Thromboembolism)",[649,650,121,651,652],"Anti-Xa","Metabolic Bariatric Surgery","VTE","DVT","2026-05-14",{"date":602,"type":39},{"date":68,"type":22},{"date":657,"type":22},"2026-12-01",{"name":659,"class":46},"University College Dublin",{"id":661,"slug":662,"hasResults":12,"nctId":663,"briefTitle":664,"officialTitle":664,"acronym":665,"eligibilityCriteria":666,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":667,"enrollmentInfo":668,"targetDuration":4,"studyType":23,"phases":670,"briefSummary":672,"conditions":673,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":676,"lastUpdatePostDateStruct":677,"startDateStruct":678,"completionDateStruct":680,"leadSponsor":682,"locationsCount":47},"100634433","phase-3-suzetrigine-enhanced-multimodal-opioid-sparing-therapy-in-cardiac-and-bariatric-surgery-100634433","NCT07539623","Suzetrigine-enhanced MultimOdal Opioid-sparing THerapy in Cardiac and Bariatric SURGery","SMOOTH-SURG","Inclusion Criteria:\n\nTo be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Adults 18-85 years old\n* Scheduled to undergo cardiac procedures via sternotomy or bariatric surgery (laparoscopic or open)\n* All genders\n\nExclusion Criteria:\n\nAny individual who meets any of the following criteria will be excluded from participation in this study:\n\n* ASA Class V\n* Urgent or emergent surgery\n* Contraindications to administration of Suzetrigine (e.g. concomitant use of strong CYP3A inhibitors)\n* History of substance use disorder or chronic opioid use\n* Reoperation\n* Patient refusal or inability to consent\n* Patients who take moderate-to-severe CYP3A inhibitors (such as Ritonavir, Voriconazole, and\n* Clarithromycin)\n* Patients who take moderate-to-severe CYP3A inducers (such as Phenytoin, Carbamazapine, and Rifabutin)","85 Years",{"count":669,"type":22},235,[671],"PHASE3","This is prospective, randomized study. The purpose of this study is to evaluate whether the addition of Suzetrigine to well established multimodal pain regimen for participants undergoing bariatric patients undergoing weight-loss surgery and cardiac patients undergoing sternotomy will reduce post-operative opioid consumption and pain scores.",[29,674,675],"Cardiac Surgery With Sternotomy","Post-operative Pain","2026-05-11",{"date":653,"type":39},{"date":679,"type":39},"2026-05-01",{"date":681,"type":22},"2026-12-22",{"name":683,"class":46},"Icahn School of Medicine at Mount Sinai",{"id":685,"slug":686,"hasResults":12,"nctId":687,"briefTitle":688,"officialTitle":689,"acronym":4,"eligibilityCriteria":690,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":691,"targetDuration":4,"studyType":23,"phases":693,"briefSummary":694,"conditions":695,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":676,"lastUpdatePostDateStruct":696,"startDateStruct":697,"completionDateStruct":699,"leadSponsor":700,"locationsCount":47},"100571534","phase-4-2024-tirzepatide-bariatric-surgery-100571534","NCT06721507","2024 Tirzepatide-Bariatric Surgery","Preoperative Tirzepatide for Bariatric Surgery","Inclusion Criteria:\n\n* adults who have been enrolled in the multidisciplinary metabolic and bariatric surgery program at the UK HealthCare Weight Loss Surgery Clinic and are scheduled to receive laparoscopic or robotic sleeve gastrectomy, or gastric bypass surgery\n* BMI greater than or equal to 40 kg\u002Fm2 with one or more obesity-related comorbidities\n* have demonstrated abstinence from any form of nicotine use, confirmed by serum nicotine and metabolite testing\n* enrollment in the ADORE Bariatric Tissue Bank (IRB #69767)\n\nExclusion Criteria:\n\n* any contraindication to the use of tirzepatide (per package insert)\n* Personal or family history of medullary thyroid carcinoma\n* Patients with Multiple Endocrine Neoplasm syndrome type 2\n* Hypersensitivity to tirzepatide\n* History of pancreatitis\n* Type 1 Diabetes\n* patients with active, untreated or symptomatic cholelithiasis or jaundice\n* consistent use of a GLP-1 or GLP-1\u002FGIP receptor agonist, over the past 90 days\n* diagnosed autoimmune disease\n* current use of immunosuppressive agents or use within the past 30 days\n* moderate or severe substance use disorder according to DSM-5 criteria\n* uncontrolled significant psychiatric disorder as assessed by specialized bariatric psychologist\n* female participant who is pregnant, breast-feeding, or intends to become pregnant with in 1 year following surgery\n* a prisoner",{"count":692,"type":22},50,[210],"This clinical trial will test whether preoperative tirzepatide treatment improves outcomes after bariatric surgery. The outcome of this study could impact therapeutic guidelines for the multimodal treatment of obesity.\n\nThe major objectives are:\n\n1. To evaluate whether pre-operative tirzepatide treatment reduces tissue and circulating inflammatory markers at the time of surgery.\n2. To establish the relationship of these changes with postoperative improvements in weight loss, metabolic and inflammatory profiles, comorbidity resolution (glycemic control, blood pressure, lipid profile), and 30-day surgical complications. Researchers will compare data from patients taking tirzepatide to data from patients not taking tirzepatide before their planned bariatric surgery to see if tirzepatide reduces inflammation and improves health outcomes after bariatric surgery.\n\nParticipants will:\n\nTake or not take tirzepatide, depending on what study group they are in, once a week for 3 months.\n\nVisit the endocrine clinic once a month for 3 months to be prescribed the drug and for checkups regarding side effects due to the drug.\n\nKeep a diary to document taking the drug and any side effects. Continue with their planned bariatric surgery and post-surgery follow-ups according to their healthcare provider.",[28,29],{"date":653,"type":39},{"date":698,"type":39},"2025-03-27",{"date":286,"type":22},{"name":701,"class":46},"Marlene Starr"]